Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Website: hillevax.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$1.21 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.0% (LTM)

Entry Point: Share price is 50.9% higher than minimum and 89.4% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: HLVX
Share price, USD:  (0.0%)2.09
year average price 1.97  


year start price 2.09 2025-01-09

min close price 1.39 2025-04-01

max close price 2.17 2025-07-14

current price 2.09 2026-01-08
Common stocks: 33 427 200

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 70
Net Debt ($m): 64
EV (Enterprise Value): 134
Price to Book: 0.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-08-19globenewswire.com

HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

2025-08-04globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)

2025-08-04prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders

2025-03-28globenewswire.com

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

2024-10-14zacks.com

What Makes HilleVax (HLVX) a New Buy Stock

2024-08-29accesswire.com

HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)

2024-08-26accesswire.com

HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX

2024-08-22accesswire.com

ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation

2024-08-08globenewswire.com

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

2024-08-07accesswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-08-06 2025-05-08 2024-11-07 2024-08-09 2024-05-09 2024-03-20 2023-11-09 2023-08-14 2023-05-12 2023-03-17 2022-11-10
acceptedDate 2025-08-06 16:15:51 2025-05-08 07:10:20 2024-11-07 08:10:22 2024-08-08 19:34:09 2024-05-09 16:15:52 2024-03-20 16:10:49 2023-11-09 16:15:47 2023-08-14 07:11:20 2023-05-12 16:16:53 2023-03-17 16:16:01 2022-11-10 16:31:54
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q2 Q1 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 3M 0 0 0 0 0
costOfRevenue 0 0 0 795 000 707 000 724 000 653 000 418 000 0 0 0
grossProfit 0 0 0 -795 000 -707 000 2M -653 000 -418 000 0 0 0
grossProfitRatio 0 0 0 0 0 0.747 0 0 0 0 0
researchAndDevelopmentExpenses 1M 2M 20M 27M 26M 33M 27M 23M 23M 18M 13M
generalAndAdministrativeExpenses 6M 6M 6M 8M 8M 7M 7M 7M 6M 6M 5M
sellingAndMarketingExpenses 0 0 0 -795 000 -707 000 -724 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 6M 6M 7M 8M 6M 7M 7M 6M 6M 5M
otherExpenses 0 0 0 1M 1M 1M 2M 329 000 2M 2M 0
operatingExpenses 7M 8M 26M 34M 34M 40M 34M 30M 29M 23M 18M
costAndExpenses 7M 8M 26M 35M 34M 40M 34M 30M 29M 23M 18M
interestIncome 746 000 776 000 1M 2M 2M 3M 2M 2M 3M 2M 1M
interestExpense 0 0 2M 738 000 727 000 726 000 -717 000 500 000 449 000 257 000 205 000
depreciationAndAmortization 478 000 490 000 842 000 795 000 707 000 724 000 653 000 418 000 361 000 1000 1M
ebitda -5M -6M -23M -39M -34M -40M -34M -27M -29M -23M -17M
ebitdaratio 0 0 0 0 0 -13.815 0 0 0 0 0
operatingIncome -7M -8M -26M -35M -34M -40M -34M -30M -29M -23M -18M
operatingIncomeRatio 0 0 0 0 0 -14.068 0 0 0 0 0
totalOtherIncomeExpensesNet 2M 2M 557 000 2M -12M 3M 2M 329 000 2M 2M 1M
incomeBeforeTax -5M -6M -26M -41M -47M -37M -32M -28M -27M -21M -17M
incomeBeforeTaxRatio 0 0 0 0 0 -12.905 0 0 0 0 0
incomeTaxExpense 0 0 0 0 663 724 3M -653 000 829 000 -3M -2M -1M
netIncome -5M -6M -26M -41M -47M -37M -32M -28M -24M -19M -16M
netIncomeRatio 0 0 0 0 0 -12.905 0 0 0 0 0
eps -0.11 -0.12 -0.52 -0.83 -0.97 -0.78 -0.81 -0.74 -0.64 -0.51 -0.42
epsdiluted -0.11 -0.12 -0.52 -0.83 -0.97 -0.78 -0.81 -0.74 -0.64 -0.51 -0.42
weightedAverageShsOut 50M 50M 49M 49M 48M 48M 39M 38M 38M 38M 37M
weightedAverageShsOutDil 50M 50M 49M 49M 48M 48M 39M 38M 38M 38M 37M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-08-06 2025-05-08 2024-11-07 2024-08-09 2024-05-09 2024-03-20 2023-11-09 2023-08-14 2023-05-12 2023-03-17 2022-11-10
acceptedDate 2025-08-06 16:15:51 2025-05-08 07:10:20 2024-11-07 08:10:22 2024-08-08 19:34:09 2024-05-09 16:15:52 2024-03-20 16:10:49 2023-11-09 16:15:47 2023-08-14 07:11:20 2023-05-12 16:16:53 2023-03-17 16:16:01 2022-11-10 16:31:54
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q2 Q1 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 59M 47M 104M 108M 141M 217M 324M 158M 261M 279M 292M
shortTermInvestments 101M 112M 86M 137M 132M 87M 116M 86M 0 0 0
cashAndShortTermInvestments 160M 160M 189M 245M 273M 303M 324M 244M 261M 279M 292M
netReceivables 0 0 0 0 77 000 0 77 000 0 0 0 0
inventory 0 0 0 0 0 0 -9M 0 0 0 0
otherCurrentAssets 3M 6M 8M 7M 8M 7M 9M 9M 9M 11M 8M
totalCurrentAssets 162M 166M 197M 253M 281M 311M 324M 253M 270M 291M 300M
propertyPlantEquipmentNet 11M 11M 22M 23M 31M 32M 32M 32M 29M 25M 20M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 2M 2M 2M 2M 2M 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 22 999 23 000 25 000 9M 23 000 2M 2M 2M
totalNonCurrentAssets 13M 13M 23M 24M 33M 34M 43M 33M 31M 27M 22M
otherAssets 0 0 0 1 0 0 0 0 0 0 0
totalAssets 175M 179M 221M 277M 314M 344M 367M 287M 301M 317M 322M
accountPayables 113 000 72 000 1M 4M 3M 7M 3M 151 000 2M 5M 875 000
shortTermDebt 4M 4M 0 33M 3M 3M 3M 437 000 38 000 37 000 34 000
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 -3M -151 000 0 0 0
otherCurrentLiabilities 2M 3M 13M 13M 19M 19M 16M 18M 17M 8M 8M
totalCurrentLiabilities 6M 7M 14M 49M 26M 29M 19M 18M 19M 13M 9M
longTermDebt 20M 20M 21M 22M 25M 25M 48M 48M 38M 36M 26M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 923 000 1M 940 000 24M 24M 1M 922 000 747 000 575 000 25M
totalNonCurrentLiabilities 21M 21M 23M 23M 50M 50M 49M 49M 39M 37M 26M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 24M 24M 21M 25M 22M 23M 26M 24M 23M 22M 21M
totalLiabilities 27M 28M 36M 72M 75M 79M 68M 68M 58M 50M 35M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 5000 5000 5000 5000 5000 5000 5000 4000 4000 4000 3000
retainedEarnings -547M -542M -502M -476M -435M -389M -352M -320M -292M -265M -244M
accumulatedOtherComprehensiveIncomeLoss -1M -1M -821 000 -937 000 -950 000 -907 000 -343 000 -322 000 -282 000 -281 000 0
othertotalStockholdersEquity 696M 694M 687M 682M 675M 655M 651M 539M 535M 532M 531M
totalStockholdersEquity 148M 151M 184M 205M 239M 266M 299M 219M 243M 267M 287M
totalEquity 148M 151M 184M 205M 239M 266M 299M 219M 243M 267M 287M
totalLiabilitiesAndStockholdersEquity 175M 179M 221M 277M 314M 344M 367M 287M 301M 317M 322M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 175M 179M 221M 277M 314M 344M 367M 287M 301M 317M 322M
totalInvestments 101M 112M 86M 138M 133M 88M 116M 86M 0 0 0
totalDebt 24M 24M 25M 51M 51M 51M 51M 49M 38M 36M 26M
netDebt -35M -23M -79M -57M -90M -165M -273M -109M -223M -243M -266M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX HLVX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-08-06 2025-05-08 2024-11-07 2024-08-09 2024-05-09 2024-03-20 2023-11-09 2023-08-14 2023-05-12 2023-03-17 2022-11-10
acceptedDate 2025-08-06 16:15:51 2025-05-08 07:10:20 2024-11-07 08:10:22 2024-08-08 19:34:09 2024-05-09 16:15:52 2024-03-20 16:10:49 2023-11-09 16:15:47 2023-08-14 07:11:20 2023-05-12 16:16:53 2023-03-17 16:16:01 2022-11-10 16:31:54
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q2 Q1 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -5M -6M -26M -41M -47M -37M -32M -28M -27M -21M -17M
depreciationAndAmortization 478 000 490 000 842 000 795 000 707 000 724 000 653 000 418 000 361 000 1000 0
deferredIncomeTax 0 0 0 0 0 5M -1M -603 000 0 0 0
stockBasedCompensation 2M 2M 5M 6M 5M 4M 4M 3M 3M 1M 844 000
changeInWorkingCapital 3M -9M 9M -3M -6M 12M 1M 2M 8M -1M -4M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -319 000 -10M -7M -3M -5M 10M -672 000 747 000 4M 4M -1M
otherWorkingCapital 3M 864 000 16M 426 000 -1M 2M 2M 1M 3M -5M -2M
otherNonCashItems -863 000 -656 000 -17M 18M 26M -5M 325 000 240 000 220 000 2M 128 000
netCashProvidedByOperatingActivities -789 000 -13M -28M -30M -33M -22M -27M -22M -16M -19M -20M
investmentsInPropertyPlantAndEquipment 0 0 14M -47 000 -14M -738 000 -2M -5M -3M -4M -185 000
acquisitionsNet 0 0 0 0 0 -30 207 -15M 0 0 0 0
purchasesOfInvestments -6M -111M -16M -47M -93M -15M -44M -85M 0 0 0
salesMaturitiesOfInvestments 18M 17M 68M 44M 49M 45M 15M 0 0 0 0
otherInvestingActivites 0 0 -15M -3421 -57 509 30 207 15M 0 0 0 0
netCashUsedForInvestingActivites 12M -94M 51M -3M -58M 29M -31M -90M -3M -4M -185 000
debtRepayment 0 0 -27M 0 0 -10M 0 -10M 0 0 0
commonStockIssued 0 0 -790 000 615 000 15M 313 000 108M 398 000 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 790 000 0 15 062 313 7000 20M 80 000 10M -3M
netCashUsedProvidedByFinancingActivities 0 0 -27M 615 000 15M 313 000 108M 10M 80 000 10M -3M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 11M -107M -3M -33M -76M 8M 50M -102M -19M -13M -23M
cashAtEndOfPeriod 60M 49M 105M 108M 141M 217M 210M 160M 262M 281M 294M
cashAtBeginningOfPeriod 49M 156M 108M 141M 217M 209M 160M 262M 281M 294M 316M
operatingCashFlow -789 000 -13M -28M -30M -33M -22M -27M -22M -16M -19M -20M
capitalExpenditure 0 0 14M -47 000 -14M -738 000 -2M -5M -3M -4M -185 000
freeCashFlow -789 000 -13M -14M -30M -47M -22M -29M -27M -19M -22M -20M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2025-08-06 20:15 ET
HilleVax, Inc. reported for 2025 q2
SEC form 8
2025-08-06 20:10 ET
HilleVax, Inc. reported for 2025 q2
SEC form 8
2025-08-06 20:10 ET
HilleVax, Inc. published news for 2025 q2
SEC form 10
2025-05-08 11:10 ET
HilleVax, Inc. reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
HilleVax, Inc. reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
HilleVax, Inc. reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
HilleVax, Inc. published news for 2025 q1
SEC form 10
2025-03-28 17:10 ET
HilleVax, Inc. reported for 2024 q4
SEC form 8
2025-03-28 17:05 ET
HilleVax, Inc. published news for 2024 q4
SEC form 8
2025-03-28 17:05 ET
HilleVax, Inc. reported for 2024 q4
SEC form 10
2025-03-28 00:00 ET
HilleVax, Inc. reported for 2024 q4
SEC form 10
2024-11-07 08:10 ET
HilleVax, Inc. reported for 2024 q3
SEC form 8
2024-11-07 08:05 ET
HilleVax, Inc. reported for 2024 q3
SEC form 8
2024-11-07 08:05 ET
HilleVax, Inc. published news for 2024 q3
SEC form 10
2024-08-09 00:00 ET
HilleVax, Inc. reported for 2024 q2
SEC form 10
2024-08-08 19:34 ET
HilleVax, Inc. reported for 2024 q2
SEC form 8
2024-08-08 19:27 ET
HilleVax, Inc. reported for 2024 q2
SEC form 8
2024-08-08 19:27 ET
HilleVax, Inc. published news for 2024 q2
SEC form 8
2024-05-09 00:00 ET
HilleVax, Inc. published news for 2024 q1
SEC form 10
2024-05-09 00:00 ET
HilleVax, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
HilleVax, Inc. reported for 2024 q1
SEC form 10
2024-03-20 16:10 ET
HilleVax, Inc. reported for 2023 q4
SEC form 8
2024-03-20 16:05 ET
HilleVax, Inc. reported for 2023 q4
SEC form 8
2024-03-20 16:05 ET
HilleVax, Inc. published news for 2023 q4
SEC form 10
2024-03-20 00:00 ET
HilleVax, Inc. reported for 2023 q4
SEC form 10
2023-11-09 16:15 ET
HilleVax, Inc. reported for 2023 q3
SEC form 8
2023-11-09 16:10 ET
HilleVax, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
HilleVax, Inc. reported for 2023 q3
SEC form 10
2023-08-14 07:11 ET
HilleVax, Inc. reported for 2023 q2
SEC form 6
2023-08-14 07:05 ET
HilleVax, Inc. reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
HilleVax, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
HilleVax, Inc. reported for 2023 q2
SEC form 6
2023-06-22 16:05 ET
HilleVax, Inc. published news for 2023 q1
SEC form 6
2023-06-13 16:41 ET
HilleVax, Inc. published news for 2023 q1
SEC form 10
2023-05-12 16:16 ET
HilleVax, Inc. reported for 2023 q1
SEC form 6
2023-05-12 16:10 ET
HilleVax, Inc. reported for 2023 q1
SEC form 8
2023-05-12 00:00 ET
HilleVax, Inc. reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
HilleVax, Inc. reported for 2023 q1
SEC form 6
2023-05-10 17:35 ET
HilleVax, Inc. published news for 2023 q1
SEC form 6
2023-05-09 07:16 ET
HilleVax, Inc. published news for 2023 q1
SEC form 6
2023-04-28 16:32 ET
HilleVax, Inc. published news for 2023 q1
SEC form 6
2023-04-25 06:51 ET
HilleVax, Inc. published news for 2023 q1
SEC form 6
2023-04-18 16:57 ET
HilleVax, Inc. published news for 2023 q1
SEC form 10
2023-03-17 16:16 ET
HilleVax, Inc. reported for 2022 q4
SEC form 6
2023-03-17 16:10 ET
HilleVax, Inc. reported for 2022 q4
SEC form 10
2023-03-17 00:00 ET
HilleVax, Inc. reported for 2022 q4
SEC form 8
2023-03-17 00:00 ET
HilleVax, Inc. reported for 2022 q4
SEC form 6
2023-01-10 17:00 ET
HilleVax, Inc. published news for 2022 q4
SEC form 6
2023-01-09 07:06 ET
HilleVax, Inc. published news for 2022 q4
SEC form 10
2022-11-10 16:31 ET
HilleVax, Inc. reported for 2022 q3
SEC form 6
2022-11-10 16:15 ET
HilleVax, Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
HilleVax, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
HilleVax, Inc. reported for 2022 q3
SEC form 6
2022-08-31 07:11 ET
HilleVax, Inc. published news for 2022 q2
SEC form 6
2022-08-23 16:35 ET
HilleVax, Inc. published news for 2022 q2
SEC form 10
2022-08-10 16:31 ET
HilleVax, Inc. reported for 2022 q2
SEC form 6
2022-08-10 16:20 ET
HilleVax, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
HilleVax, Inc. reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
HilleVax, Inc. reported for 2022 q2
SEC form 10
2022-06-08 16:25 ET
HilleVax, Inc. reported for 2022 q1
SEC form 6
2022-06-08 16:16 ET
HilleVax, Inc. published news for 2022 q1
SEC form 8
2022-06-08 00:00 ET
HilleVax, Inc. reported for 2022 q1
SEC form 10
2022-06-08 00:00 ET
HilleVax, Inc. reported for 2022 q1
SEC form 6
2022-05-03 16:15 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:48 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:47 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:45 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:45 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:42 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:39 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:34 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:33 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:30 ET
HilleVax, Inc. published news for 2022 q1
SEC form 6
2022-04-28 21:29 ET
HilleVax, Inc. published news for 2022 q1